Follow
SYRIGOS KONSTANTINOS N.
SYRIGOS KONSTANTINOS N.
Verified email at med.uoa.gr
Title
Cited by
Cited by
Year
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
25142017
Nivolumab plus ipilimumab in advanced non–small-cell lung cancer
MD Hellmann, L Paz-Ares, R Bernabe Caro, B Zurawski, SW Kim, ...
New England Journal of Medicine 381 (21), 2020-2031, 2019
22982019
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy …
EB Garon, TE Ciuleanu, O Arrieta, K Prabhash, KN Syrigos, T Goksel, ...
The Lancet 384 (9944), 665-673, 2014
14032014
Programmed death ligand-1 expression in non-small cell lung cancer
V Velcheti, KA Schalper, DE Carvajal, VK Anagnostou, KN Syrigos, ...
Laboratory investigation 94 (1), 107-116, 2014
9252014
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
D Farge, P Debourdeau, M Beckers, C Baglin, RM Bauersachs, B Brenner, ...
Journal of Thrombosis and Haemostasis 11 (1), 56-70, 2013
6872013
Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action
A Kollias, KG Kyriakoulis, E Dimakakos, G Poulakou, GS Stergiou, ...
British journal of haematology 189 (5), 846-847, 2020
6252020
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
J Vansteenkiste, L Crino, C Dooms, JY Douillard, C Faivre-Finn, E Lim, ...
Annals of Oncology 25 (8), 1462-1474, 2014
5442014
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal …
J Souglakos, N Androulakis, K Syrigos, A Polyzos, N Ziras, ...
British journal of cancer 94 (6), 798-805, 2006
5222006
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix, L Paz-Ares, CH Chiu, ...
The Lancet Oncology 20 (12), 1655-1669, 2019
5192019
Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer
V Michalaki, K Syrigos, P Charles, J Waxman
British journal of cancer 90 (12), 2312-2316, 2004
5132004
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
JC Soria, E Felip, M Cobo, S Lu, K Syrigos, KH Lee, E Göker, ...
The lancet oncology 16 (8), 897-907, 2015
5062015
Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 …
SG Deftereos, G Giannopoulos, DA Vrachatis, GD Siasos, SG Giotaki, ...
JAMA network open 3 (6), e2013136-e2013136, 2020
4662020
Cell adhesion molecules: role and clinical significance in cancer
N Makrilia, A Kollias, L Manolopoulos, K Syrigos
Cancer investigation 27 (10), 1023-1037, 2009
4502009
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
WEE Eberhardt, D De Ruysscher, W Weder, C Le Pechoux, P De Leyn, ...
Annals of Oncology 26 (8), 1573-1588, 2015
4072015
Objective measurement and clinical significance of TILs in non–small cell lung cancer
KA Schalper, J Brown, D Carvajal-Hausdorf, J McLaughlin, V Velcheti, ...
Journal of the National Cancer Institute 107 (3), dju435, 2015
4012015
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer
P Debourdeau, D Farge, M Beckers, C Baglin, RM Bauersachs, B Brenner, ...
Journal of Thrombosis and Haemostasis 11 (1), 71-80, 2013
3722013
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
KM Kerr, L Bubendorf, MJ Edelman, A Marchetti, T Mok, S Novello, ...
Annals of Oncology 25 (9), 1681-1690, 2014
3632014
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
B Besse, A Adjei, P Baas, P Meldgaard, M Nicolson, L Paz-Ares, M Reck, ...
Annals of Oncology 25 (8), 1475-1484, 2014
2892014
Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery
D Alexiou, AJ Karayiannakis, KN Syrigos, A Zbar, A Kremmyda, I Bramis, ...
European Journal of Cancer 37 (18), 2392-2397, 2001
2742001
Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non–small cell lung cancer using spatially resolved and multiparametric single-cell analysis
I Datar, MF Sanmamed, J Wang, BS Henick, J Choi, T Badri, W Dong, ...
Clinical Cancer Research 25 (15), 4663-4673, 2019
2632019
The system can't perform the operation now. Try again later.
Articles 1–20